United States SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

Generation Bio Co.

(Name of Issuer)

Common Stock (Title of Class of Securities)

> 37148K100 (CUSIP Number)

December 31, 2020 (Date of Event Which Requires Filing This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

□ Rule 13d-1(b) ⊠ Rule 13d-1(c) □ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 37148K100

1	M	. C D	an article Diversion			
1.	Names of Reporting Persons					
	BB Biotech AG					
2. Check the Appropriate Box if a Member of a Group (See Instructions)						
	(a) 🗵	(b) 🗆			
3.	SEC Us	se O	nly			
4.	Citizen	ship	or Place of Organization			
	Switz	erla				
		5.	Sole Voting Power			
Nu	nber of		0			
	hares	6.	Shared Voting Power			
	eficially					
	ned by		2,393,180			
	Each	7.	Sole Dispositive Power			
	porting	, .				
	erson		0			
V	with:	8.	Shared Dispositive Power			
		0.	Shared Dispositive Fower			
			2,393,180			
9.	A		Amount Beneficially Owned by Each Reporting Person			
9.	Aggreg	ale A	Amount Beneficially Owned by Each Reporting Person			
	2 202	100				
10	2,393,180					
10.	Check	t the	e Aggregate Amount in Row (9) Excludes Certain Shares			
	_					
11.	11. Percent of Class Represented by amount in Row (9)					
	5.1%					
12.	12. Type of Reporting Person (See Instructions)					
	нс,со					

CUSIP No. 37148K100

1.	1. Names of Reporting Persons						
	Biotech Growth N.V.						
	I.R.S. Identification Nos. of above persons (entities only):						
	N/A						
2.		he A	Appropriate Box if a Member of a Group (See Instructions)				
2.	(a) \boxtimes		b)				
3.	3. SEC Use Only						
4.	Citizen	ship	or Place of Organization				
	C						
	Cura		Col. M. Constant				
		5.	Sole Voting Power				
			0				
	nber of hares	6.	Shared Voting Power				
	nares eficially						
	ned by		2,393,180				
	Each	7.	Sole Dispositive Power				
	porting erson						
	with:	-	0				
	vitili.	8.	Shared Dispositive Power				
			2,393,180				
9.	Aggreg	ate /	Amount Beneficially Owned by Each Reporting Person				
).	7. Aggregate Amount Beneficially Owned by Each Reporting Person						
	2,393,180						
10.							
11.	1. Percent of Class Represented by amount in Row (9)						
10	5.1%						
12.	12. Type of Reporting Person (See Instructions)						
	СО						

Item	1

- 1(a) Name of Issuer: <u>Generation Bio Co.</u>
- 1(b)Address of Issuer's Principal Executive Offices:301 Binney Street, Cambridge, MA, 02142 United States

Item 2

- 2(a) Name of Person Filing: <u>BB Biotech AG ("BB Biotech") on behalf of its wholly-owned subsidiary, Biotech Growth N.V. ("Biotech Growth")</u>
 - 2(b) Address of Principal Business Office or, if none, Residence: <u>BB Biotech AG: Schwertstrasse 6, CH-8200 Schaffhausen, Switzerland</u> <u>Biotech Growth N.V.: Ara Hill Top Building, Unit A-5, Pletterijweg Oost 1, Curaçao</u>
 - 2(c) Citizenship: <u>BB Biotech AG: Switzerland</u> <u>Biotech Growth N.V.: Curacao</u>
 - 2(d) Title of Class of Securities <u>Common Stock, \$0.0001 par value</u>
 - 2(e) CUSIP Number <u>37148K100</u>

Item 3

If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

- a. \Box Broker or Dealer registered under Section 15 of the Act.
- b. \Box Bank as defined in Section 3(a)(6) of the Act.
- c. \Box Insurance company as defined in Section 3(a)(19) of the Act.
- d. 🛛 Investment company registered under section 8 of the Investment Company Act of 1940.
- f. \Box An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
- g. \Box A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- h. 🗆 A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- i. 🗆 A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in

- Item 1.
 - (a) Amount beneficially owned: 2,393,180
 - (b) Percent of class: <u>5.1%</u>
 - (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote <u>0</u>
 - (ii) Shared power to vote or to direct the vote <u>2,393,180</u>
 - (iii) Sole power to dispose or to direct the disposition of <u>0</u>
 - (iv) Shared power to dispose or to direct the disposition of <u>2,393,180</u>

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: \Box

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

This statement is filed jointly by BB Biotech and Biotech Growth, Biotech Growth is a wholly-owned subsidiary of BB Biotech.

Item 8. Identification and Classification of Members of the Group

N/A

Item 9. Notice of Dissolution of Group

N/A

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURES

After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BB Biotech AG

Date: January 6, 2021	By:	/s/ Martin Gubler
		Signatory Authority
	Name:	Martin Gubler
	Title:	Signatory Authority
Date: January 6, 2021	By:	/s/ Ivo Betschart
		Signatory Authority
	Name:	Ivo Betschart
	Title:	Signatory Authority
Biotech Growth N.V.		
Date: January 6, 2021	By:	/s/ Jan Bootsma
		Signatory Authority
	Name:	Jan Bootsma
	Title:	Signatory Authority
Date: January 6, 2021	Ву:	/s/ Hugo van Neutegem
		Signatory Authority
	Name:	Hugo van Neutegem
	Title:	Signatory Authority
	6 of 7	

<u>Exhibit A</u> Joint Filing Statement

We, the undersigned, hereby express our agreement that the attached Schedule 13G (including all amendments thereto) is filed on behalf of each of the undersigned.

		BB Biotech AG
Date: January 6, 2021	By:	/s/ Martin Gubler
		Signatory Authority
	Name:	Martin Gubler
	Title:	Signatory Authority
Date: January 6, 2021	By:	/s/ Ivo Betschart
		Signatory Authority
	Name:	Ivo Betschart
	Title:	Signatory Authority
		Biotech Growth N.V.
Date: January 6, 2021	By:	/s/ Jan Bootsma
		Signatory Authority
	Name:	Jan Bootsma
	Title:	Signatory Authority
Date: January 6, 2021	By:	/s/ Hugo van Neutegem
		Signatory Authority
	Name:	Hugo van Neutegem
	Title:	Signatory Authority
	7 of 7	